Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Synthetic

BZO-POXIZID

An OXIZID synthetic cannabinoid, a full agonist at CB1; a narcotic in France since the ANSM decision of 22 May 2024.

Narcotic: named in schedule
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₀H₂₁N₃O₂

CAS 1048973-64-3

Family
Synthetic CB receptor agonistNew psychoactive substance
Molar mass
335.41 g/mol

Updated on

In plain terms

BZO-POXIZID is a synthetic cannabinoid made in the laboratory, with no link to hemp. It belongs to a family that appeared after the Chinese generic ban of July 2021, and it has been detected in seized powders and vaping liquids. It has been classed as a narcotic in France since the ANSM decision of 22 May 2024, and its effects in humans have not been studied.

Receptors and activity

Target network

CB1Agonistno measured value
  • Activates

The lower the cited value, the closer the target sits to BZO-POXIZID: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of BZO-POXIZID.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1Agonistno measured value cited
  2. CB2Partial agonistno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

BZO-POXIZID belongs to the OXIZID class, isatin acylhydrazones whose emergence followed the Chinese generic legislation of July 2021 (Deventer et al. 2022). Its lead compound, MDA-19, was described in 2008 as a selective CB2 agonist (Diaz et al. 2008); shortening the hexyl chain to pentyl increases activity at both receptors. In β-arrestin 2 recruitment assays, OXIZIDs are full agonists at CB1 and partial agonists at CB2, and BZO-POXIZID is the only one in the tested series not to prefer CB2 (Deventer et al. 2022). Patel et al. (2024) place OXIZIDs behind earlier generations of synthetic cannabinoids, in both potency and efficacy. Liu et al. (2022) detected it for the first time on the recreational market, with 5F-MDA-19, in Chinese seizures. Five cases of unintentional exposure to an analogue, BZO-4en-POXIZID, were identified by hair analysis in people attending New York nightclubs (Palamar et al. 2024). No clinical study, no human pharmacokinetics and no published poisoning case specific to this molecule were found in the sources consulted.

Key sources.

History

Source
A wholly synthetic molecule, absent from hemp and from any other plant. According to Deventer et al. (2022), the appearance of OXIZIDs followed the Chinese generic legislation of July 2021, which pushed manufacturers towards replacement scaffolds. Liu et al. (2022) detected this compound (« pentyl MDA-19 ») for the first time on the recreational market, in powders and vaping liquids seized in China.

Origin

Laboratory synthesis

No known biosynthetic pathway: BZO-POXIZID comes from no living organism and has never been detected in a plant. It is an N-pentylated isatin acylhydrazone (oxindol-3-ylidene benzohydrazide), described here by its chemical class only.

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

oxoindole (OXIZID)

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

No dedicated article.

References

  1. Diaz et al. · J Med Chem 2008 (new tab)PMID 18666769
  2. Deventer et al. · Drug Test Anal 2022 (new tab)PMID 35560866
  3. Liu et al. · Drug Test Anal 2022 (new tab)PMID 34694738
  4. Patel et al. · Eur J Pharmacol 2024 (new tab)PMID 38561104
  5. Lee et al. · Clin Chem 2022 (new tab)PMID 36175111
  6. Watanabe et al. · J Anal Toxicol 2023 (new tab)PMID 36857377
  7. Palamar et al. · J Anal Toxicol 2024 (new tab)PMID 37952092
  8. Sekuła et al. · J Am Soc Mass Spectrom 2025 (new tab)PMID 40193255
  9. Xu et al. · J Appl Toxicol 2025 (new tab)PMID 39477463

Identifiers

Names

IUPAC name
N-(2-hydroxy-1-pentylindol-3-yl)iminobenzamide
Other names
5C-MDA-19 · Pentyl MDA-19

Identifiers

Formula
C₂₀H₂₁N₃O₂
CAS
1048973-64-3
PubChem CID
2691386(new tab)
InChIKey
XPLMQEMEOJHAQP-UHFFFAOYSA-N
SMILES
CCCCCN1C2=CC=CC=C2C(=C1O)N=NC(=O)C3=CC=CC=C3

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.